Intra-Cellular Therapies, Inc.
ITCI evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $9.00B
- Lead Asset:
- Caplyta (Approved)
What it means
What to watch
Prepared research question
What matters most for ITCI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates · 15 clinical trials · 1 FDA decision for Intra-Cellular Therapies, Inc..
Run Intra-Cellular Therapies, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Intra-Cellular Therapies, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Intra-Cellular Therapies, Inc.'s lead drug candidate?
Intra-Cellular Therapies, Inc.'s most advanced tracked candidate is Caplyta (Approved) for Schizophrenia (adults); Bipolar depression (adults).
Who is the CEO of Intra-Cellular Therapies, Inc.?
Chief Executive Officer is the chief executive officer of Intra-Cellular Therapies, Inc. (ITCI).
What therapeutic areas does Intra-Cellular Therapies, Inc. focus on?
Intra-Cellular Therapies, Inc. develops therapies across Oncology, Neurology, Immunology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.